Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 1 Single Center, Non-randomized Study Evaluating Safety and Efficacy of Anti-CD19 Chimeric Antigen Receptor T-cell (C-CAR011) Treatment in Subjects With Refractory Diffuse Large B-cell Lymphoma
Brief Summary: The trial is a single arm, single-center, non-randomized phase I clinical trial which is designed to evaluate the safety and efficacy of C-CAR011 in treatment of refractory DLBCL


Options:
A: Arm Label: C-CAR011; Type: EXPERIMENTAL; Interventions: Biological: C-CAR-011 | Intervention Type: BIOLOGICAL; Name: C-CAR-011; Assigned to Arm(s): C-CAR011
B: Arm Label: Administration of JCAR017; Type: EXPERIMENTAL; Interventions: Drug: JCAR017 | Intervention Type: DRUG; Name: JCAR017; Assigned to Arm(s): Administration of JCAR017
C: Arm Label: CAR-20/19-T cells (1.0 x10^5 CAR-20/19-T cells/kg); Type: EXPERIMENTAL; Interventions: Biological: CAR-20/19-T cells (1.0 x10^5 CAR-20/19-T cells/kg) | Arm Label: CAR-20/19-T cells (2.5 x10^5 CAR-20/19-T cells/kg); Type: EXPERIMENTAL; Interventions: Biological: CAR-20/19-T cells (2.5 x10^5 CAR-20/19-T cells/kg) | Arm Label: CAR-20/19-T cells (7.5 x10^5 CAR-20/19-T cells/kg); Type: EXPERIMENTAL; Interventions: Biological: CAR-20/19-T cells (7.5 x10^5 CAR-20/19-T cells/kg) | Arm Label: CAR-20/19-T cells (2.5 x10^6 CAR-20/19-T cells/kg); Type: EXPERIMENTAL; Interventions: Biological: CAR-20/19-T cells (2.5 x10^6 CAR-20/19-T cells/kg) | Intervention Type: BIOLOGICAL; Name: CAR-20/19-T cells (1.0 x10^5 CAR-20/19-T cells/kg); Assigned to Arm(s): CAR-20/19-T cells (1.0 x10^5 CAR-20/19-T cells/kg) | Intervention Type: BIOLOGICAL; Name: CAR-20/19-T cells (2.5 x10^5 CAR-20/19-T cells/kg); Assigned to Arm(s): CAR-20/19-T cells (2.5 x10^5 CAR-20/19-T cells/kg) | Intervention Type: BIOLOGICAL; Name: CAR-20/19-T cells (7.5 x10^5 CAR-20/19-T cells/kg); Assigned to Arm(s): CAR-20/19-T cells (7.5 x10^5 CAR-20/19-T cells/kg) | Intervention Type: BIOLOGICAL; Name: CAR-20/19-T cells (2.5 x10^6 CAR-20/19-T cells/kg); Assigned to Arm(s): CAR-20/19-T cells (2.5 x10^6 CAR-20/19-T cells/kg)
D: Arm Label: Phase 1 Study: Axicabtagene Ciloleucel and Conditioning Chemotherapy; Type: EXPERIMENTAL; Interventions: Biological: Axicabtagene Ciloleucel, Drug: Fludarabine, Drug: Cyclophosphamide | Arm Label: Phase 2 (Pivotal Study): Cohort 1; Type: EXPERIMENTAL; Interventions: Biological: Axicabtagene Ciloleucel, Drug: Fludarabine, Drug: Cyclophosphamide | Arm Label: Phase 2 (Pivotal Study): Cohort 2; Type: EXPERIMENTAL; Interventions: Biological: Axicabtagene Ciloleucel, Drug: Fludarabine, Drug: Cyclophosphamide | Arm Label: Phase 2 (Safety Management Study): Cohort 3; Type: EXPERIMENTAL; Interventions: Biological: Axicabtagene Ciloleucel, Drug: Fludarabine, Drug: Cyclophosphamide, Drug: Levetiracetam, Drug: Tocilizumab | Arm Label: Phase 2 (Safety Management Study): Cohort 4; Type: EXPERIMENTAL; Interventions: Biological: Axicabtagene Ciloleucel, Drug: Fludarabine, Drug: Cyclophosphamide, Drug: Levetiracetam, Drug: Tocilizumab, Drug: Dexamethasone, Drug: High-dose methylprednisolone, Drug: Bendamustine, Drug: Rituximab | Arm Label: Phase 2 (Safety Management Study): Cohort 5; Type: EXPERIMENTAL; Interventions: Biological: Axicabtagene Ciloleucel, Drug: Fludarabine, Drug: Cyclophosphamide, Drug: Levetiracetam, Drug: Rituximab, Drug: Doxorubicin, Drug: Prednisone, Drug: Vincristine, Drug: Ifosfamide, Drug: Carboplatin, Drug: Etoposide, Drug: Gemcitabine, Drug: Oxaliplatin, Drug: Cisplatin | Arm Label: Phase 2 (Safety Management Study): Cohort 6; Type: EXPERIMENTAL; Interventions: Biological: Axicabtagene Ciloleucel, Drug: Fludarabine, Drug: Cyclophosphamide, Drug: Levetiracetam, Drug: Tocilizumab, Drug: Dexamethasone, Drug: High-dose methylprednisolone, Drug: Bendamustine, Drug: Rituximab, Drug: Methylprednisolone | Intervention Type: BIOLOGICAL; Name: Axicabtagene Ciloleucel; Assigned to Arm(s): Phase 1 Study: Axicabtagene Ciloleucel and Conditioning Chemotherapy, Phase 2 (Pivotal Study): Cohort 1, Phase 2 (Pivotal Study): Cohort 2, Phase 2 (Safety Management Study): Cohort 3, Phase 2 (Safety Management Study): Cohort 4, Phase 2 (Safety Management Study): Cohort 5, Phase 2 (Safety Management Study): Cohort 6 | Intervention Type: DRUG; Name: Fludarabine; Assigned to Arm(s): Phase 1 Study: Axicabtagene Ciloleucel and Conditioning Chemotherapy, Phase 2 (Pivotal Study): Cohort 1, Phase 2 (Pivotal Study): Cohort 2, Phase 2 (Safety Management Study): Cohort 3, Phase 2 (Safety Management Study): Cohort 4, Phase 2 (Safety Management Study): Cohort 5, Phase 2 (Safety Management Study): Cohort 6 | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Phase 1 Study: Axicabtagene Ciloleucel and Conditioning Chemotherapy, Phase 2 (Pivotal Study): Cohort 1, Phase 2 (Pivotal Study): Cohort 2, Phase 2 (Safety Management Study): Cohort 3, Phase 2 (Safety Management Study): Cohort 4, Phase 2 (Safety Management Study): Cohort 5, Phase 2 (Safety Management Study): Cohort 6 | Intervention Type: DRUG; Name: Levetiracetam; Assigned to Arm(s): Phase 2 (Safety Management Study): Cohort 3, Phase 2 (Safety Management Study): Cohort 4, Phase 2 (Safety Management Study): Cohort 5, Phase 2 (Safety Management Study): Cohort 6 | Intervention Type: DRUG; Name: Tocilizumab; Assigned to Arm(s): Phase 2 (Safety Management Study): Cohort 3, Phase 2 (Safety Management Study): Cohort 4, Phase 2 (Safety Management Study): Cohort 6 | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Phase 2 (Safety Management Study): Cohort 4, Phase 2 (Safety Management Study): Cohort 6 | Intervention Type: DRUG; Name: High-dose methylprednisolone; Assigned to Arm(s): Phase 2 (Safety Management Study): Cohort 4, Phase 2 (Safety Management Study): Cohort 6 | Intervention Type: DRUG; Name: Bendamustine; Assigned to Arm(s): Phase 2 (Safety Management Study): Cohort 4, Phase 2 (Safety Management Study): Cohort 6 | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): Phase 2 (Safety Management Study): Cohort 4, Phase 2 (Safety Management Study): Cohort 5, Phase 2 (Safety Management Study): Cohort 6 | Intervention Type: DRUG; Name: Doxorubicin; Assigned to Arm(s): Phase 2 (Safety Management Study): Cohort 5 | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): Phase 2 (Safety Management Study): Cohort 5 | Intervention Type: DRUG; Name: Vincristine; Assigned to Arm(s): Phase 2 (Safety Management Study): Cohort 5 | Intervention Type: DRUG; Name: Ifosfamide; Assigned to Arm(s): Phase 2 (Safety Management Study): Cohort 5 | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Phase 2 (Safety Management Study): Cohort 5 | Intervention Type: DRUG; Name: Etoposide; Assigned to Arm(s): Phase 2 (Safety Management Study): Cohort 5 | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): Phase 2 (Safety Management Study): Cohort 5 | Intervention Type: DRUG; Name: Oxaliplatin; Assigned to Arm(s): Phase 2 (Safety Management Study): Cohort 5 | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Phase 2 (Safety Management Study): Cohort 5 | Intervention Type: DRUG; Name: Methylprednisolone; Assigned to Arm(s): Phase 2 (Safety Management Study): Cohort 6

Answer: A